Part 2Viral vaccines

Part 2 Viral vaccines

<table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><thead><tr><td style="width:5.44%; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead" style="text-align:right"><span>Item</span></p></td><td style="width:31.08%; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine and the circumstances in which vaccine may be provided</span></p></td><td colspan="2" style="border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Brand</span></p></td><td style="width:13.24%; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Formulation</span></p></td><td style="width:23.42%; border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Active ingredient and strength</span></p></td><td colspan="2" style="border-bottom:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Number and timing of doses</span></p></td></tr></thead><tbody><tr><td style="width:5.44%; border-top:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>201</span></p></td><td style="width:31.08%; border-top:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Hepatitis A (monovalent)</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to a child:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>who is Aboriginal and/or Torres Strait Islander; and</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>who is at least 1 year old but less than 5</span><span> </span><span>years of age; and</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>who lives in Queensland, Western Australia, South Australia or the Northern</span><span> </span><span>Territory</span></p></td><td colspan="2" style="border-top:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>VAQTA Paediatric/ Adolescent</span></p></td><td style="width:13.24%; border-top:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; border-top:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Hepatitis A virus protein</span><span> </span><span>— 25</span><span> </span><span>units of the hepatitis A virus protein</span></p></td><td colspan="2" style="border-top:0.75pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>2 doses, with the second dose given 6</span><span> </span><span>months after the first dose</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>202</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Hepatitis B (monovalent adult)</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to a child who is at least 10</span><span> </span><span>years old but less than 14</span><span> </span><span>years of age.</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>H</span><span>‑</span><span>B</span><span>‑</span><span>Vax II</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Vial for injection (1mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Hepatitis B surface antigen protein</span><span> </span><span>— 10</span><span> </span><span>µg</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>2 doses, with the second dose given 4 to 6</span><span> </span><span>months after the first dose</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>202A</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt; background-color:#ffffff"><span>Hepatitis B (monovalent adult)</span></p><p class="TableColHead"><span>Circumstances</span></p><p><span>Vaccine may be provided to a child who is at least 10 years old but less than 14 years of age until either:</span></p><p style="margin-left:37.1pt; text-indent:-36pt"><span>(i)</span><span style="width:25.62pt; text-indent:0pt; display:inline-block"> </span><span>the Department has been notified by the person who is the responsible person for the supply of item 202 of Schedule 1, that item 202 is available for supply in Australia; and</span></p><p style="margin-left:37.1pt; text-indent:-36pt"><span>(ii)</span><span style="width:22.56pt; text-indent:0pt; display:inline-block"> </span><span>the information provided by the responsible person is sufficient to satisfy the Department to that effect; or</span></p><p style="margin-left:37.1pt; text-indent:-36pt"><span>(iii)</span><span style="width:19.51pt; text-indent:0pt; display:inline-block"> </span><span>the end of 30 June 2022;</span></p><p><span>whichever were to occur first.</span></p><p style="margin-left:37.1pt; text-indent:-36pt"><span>(iv)</span><span style="width:20.12pt; text-indent:0pt; display:inline-block"> </span><span>the Department has been notified by the person who is the responsible person for the supply of item 202 of Schedule 1, that item 202 is available for supply in Australia; and (v)</span><span> </span><span>the information provided by the responsible person is sufficient to satisfy the Department to that effect; or</span></p><p style="margin-left:37.1pt; text-indent:-36pt"><span>(v)</span><span style="width:23.17pt; text-indent:0pt; display:inline-block"> </span><span>the end of 30 June 2022;</span></p><p><span>whichever were to occur first.</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Engerix</span><span>‑</span><span>B</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (1mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span style="background-color:#ffffff">Hepatitis B surface antigen protein </span><span style="background-color:#ffffff">‑</span><span style="background-color:#ffffff"> 20μg</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span style="background-color:#ffffff">2 doses, with the second dose given 4 to 6 months after the first dose</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>203</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Hepatitis B (monovalent paediatric)</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided in the circumstances set out in subsection</span><span> </span><span>7</span><span> </span><span>(4)</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Engerix</span><span>‑</span><span>B</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Vial for injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Hepatitis B surface antigen protein</span><span> </span><span>— 10</span><span> </span><span>µg</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>1 dose or 3</span><span> </span><span>doses</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>204</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Hepatitis B (monovalent paediatric)</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to a newborn infant as soon as practicable after birth but no later than 7</span><span> </span><span>days after birth.</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>H</span><span>‑</span><span>B</span><span>‑</span><span>Vax II</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Vial for injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Hepatitis B surface antigen protein</span><span> </span><span>— 5 µg</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>1 dose</span></p></td></tr><tr style="height:297.05pt"><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>205</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Influenza</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided in the circumstances set out in subsection</span><span> </span><span>7</span><span> </span><span>(5)</span></p><p><span></span></p><p><span></span></p><p><span></span></p><p><span></span></p><p><span></span></p><p><span></span></p><p><span></span></p><p><span></span></p><p><span></span></p><p><span></span></p><p><span></span></p><p><span></span></p><p><span></span></p><p><span style="width:161.6pt; display:inline-block"></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Influvac or Fluarix</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p><p class="TableText0"><span></span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableP1a"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>For children older than 6</span><span> </span><span>months but less than 9</span><span> </span><span>years, 2</span><span> </span><span>doses at least 1month apart for the first vaccination and 1 dose per calendar year after that. For persons 9</span><span> </span><span>years and above, 1 dose per calendar year.</span></p><p class="TableText0"><span>Note – For children aged between 6</span><span> </span><span>months and less than 3</span><span> </span><span>years the dose is 0.25ml</span></p></td></tr><tr style="height:63.15pt"><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>206</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Influenza</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided in the circumstances set out in subsection</span><span> </span><span>7</span><span> </span><span>(6)</span></p><p class="TableColHead"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Intanza 15 micrograms</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.1mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableP1a"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>For persons aged 65 years and over. 1</span><span> </span><span>dose per calendar year.</span></p></td></tr><tr style="height:63.15pt"><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>207</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Influenza</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided in the circumstances set out in subsection</span><span> </span><span>7</span><span> </span><span>(7)</span></p><p class="TableColHead"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Fluvax</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p><p class="TableText0"><span></span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableP1a"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>For children older than 5</span><span> </span><span>years but less than 9</span><span> </span><span>years, 2</span><span> </span><span>doses at least 1 month apart for the first vaccination and 1 dose per calendar year after that. For persons 9</span><span> </span><span>years and above, 1 dose per calendar year.</span></p></td></tr><tr style="height:148.15pt"><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span style="font-style:italic"></span><span>207A</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:6pt; margin-bottom:3pt; page-break-after:avoid; line-height:10pt"><span style="font-family:Arial, sans-serif; font-size:9pt; font-weight:bold">Vaccine</span></p><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Influenza</span></p><p style="margin-top:6pt; margin-bottom:3pt; page-break-after:avoid; line-height:10pt"><span style="font-family:Arial, sans-serif; font-size:9pt; font-weight:bold">Circumstances</span></p><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Vaccine may be provided in the circumstances set out in subsection 7(8)</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Fluarix Tetra</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-left:26.65pt; margin-bottom:3pt; text-indent:-26.65pt; line-height:12pt"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>For children 6 months and older but less than 9 years, 2 doses at least 1 month apart for the first vaccination and 1 dose per calendar year after that.</span><span> </span><span>For persons 9 years and above, 1 dose per calendar year.</span></p></td></tr><tr style="height:148.15pt"><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span style="font-style:italic"></span><span>207B</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:6pt; margin-bottom:3pt; page-break-after:avoid; line-height:10pt"><span style="font-family:Arial, sans-serif; font-size:9pt; font-weight:bold">Vaccine</span></p><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Influenza</span></p><p style="margin-top:6pt; margin-bottom:3pt; page-break-after:avoid; line-height:10pt"><span style="font-family:Arial, sans-serif; font-size:9pt; font-weight:bold">Circumstances</span></p><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Vaccine may be provided in the circumstances set out in subsection 7(8).</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>FluQuadri</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-left:26.65pt; margin-bottom:3pt; text-indent:-26.65pt; line-height:12pt"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>For children aged 6 months and older, but less than 9 years – 2 doses at least 1 month apart for the first vaccination and 1 dose per calendar year after that.</span></p><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>For persons 9 years and above, 1 dose per calendar year.</span></p></td></tr><tr style="height:148.15pt"><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>207C</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Influenza</span></p><p class="TableColHead"><span>Circumstances</span></p><p style="margin-top:6pt; margin-bottom:3pt; page-break-after:avoid; line-height:10pt"><span>Vaccine may be provided in the circumstances set out in subsection</span><span> </span><span>7</span><span> </span><span>(8A).</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Afluria Quad</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-left:26.65pt; margin-bottom:3pt; text-indent:-26.65pt; line-height:12pt"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>1 dose per calendar year.</span></p></td></tr><tr style="height:148.15pt"><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>207D</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Influenza</span></p><p class="TableColHead"><span>Circumstances</span></p><p style="margin-top:6pt; margin-bottom:3pt; page-break-after:avoid; line-height:10pt"><span>Vaccine may be provided to a person who is at least 65 years of age.</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Fluzone High Dose</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-left:26.65pt; margin-bottom:3pt; text-indent:-26.65pt; line-height:12pt"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>1 dose per calendar year</span></p></td></tr><tr style="height:148.15pt"><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>207E</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Influenza</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to a person who is at least 65 years of age.</span></p></td><td style="width:13.68%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Fluad</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="margin-top:0pt; margin-bottom:0pt; line-height:normal"><span></span></p></td><td style="width:13.04%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>1 dose per calendar year</span></p></td><td style="vertical-align:top"></td></tr><tr style="height:148.15pt"><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="margin-top:11pt; text-align:right"><span>207F</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="line-height:normal; font-size:9pt"><span style="font-family:Arial, sans-serif; font-weight:bold"></span></p><p class="TableColHead" style="margin-top:0pt"><span>Vaccine</span></p><p class="TableText0"><span>Influenza</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided in the circumstances set out in subsection 7(8)</span></p></td><td style="width:13.68%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="margin-top:11pt"><span>VaxiGrip Tetra</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="margin-top:11pt"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="margin-top:0pt; margin-bottom:0pt; line-height:normal"><span></span></p></td><td style="width:13.04%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="margin-top:11pt"><span>For children older than 6 months but less than 9 years, 2 doses at least 1month apart for the first vaccination and 1 dose per calendar year after that. For persons 9 years and above, 1 dose per calendar year.</span></p></td><td style="vertical-align:top"></td></tr><tr style="height:148.15pt"><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>207G</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Influenza</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to a person who is at least 65 years of age.</span></p></td><td style="width:13.68%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Fluad Quad</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span></span></p></td><td style="width:13.04%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>1 dose per calendar year.</span></p></td><td style="vertical-align:top"></td></tr><tr style="height:148.15pt"><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>208</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Influenza</span></p><p class="TableColHead"><span>Circumstances</span></p><p style="margin-top:6pt; margin-bottom:3pt; page-break-after:avoid; line-height:10pt"><span>Vaccine may be provided to a child that is older than 6 months but less than 3 years, in the circumstances set out in subsection</span><span> </span><span>7</span><span> </span><span>(5)(c).</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Vaxigrip Junior</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Injection (0.25mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-left:26.65pt; margin-bottom:3pt; text-indent:-26.65pt; line-height:12pt"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>For children older than 6</span><span> </span><span>months but less than 3</span><span> </span><span>years, 2</span><span> </span><span>doses at least 1 month apart for the first vaccination and 1 dose per calendar year after that.</span></p></td></tr><tr style="height:155.25pt"><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>208A</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableColHead"><span style="font-family:'Times New Roman', serif; font-size:11pt; font-weight:normal">Influenza</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableColHead"><span style="font-family:'Times New Roman', serif; font-size:11pt; font-weight:normal">Vaccine may be provided in the circumstances set out in subsection 7(9)</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>FluQuadri Junior</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.25mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableP1a" style="margin-left:0pt; text-indent:0pt"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>For children 6</span><span> </span><span>months and older but less than 3 years, 2 doses at least 1 month apart for the first vaccination and 1 dose per calendar year after that.</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>209</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Influenza</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided in the circumstances set out in subsection 7(5).</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Agrippal</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableP1a"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>For children older than 6</span><span> </span><span>months but less than 9</span><span> </span><span>years, 2</span><span> </span><span>doses at least 1month apart for the first vaccination and 1 dose per calendar year after that. For persons 9</span><span> </span><span>years and above, 1 dose per calendar year.</span></p><p class="TableText0"><span>Note – For children aged between 6</span><span> </span><span>months and less than 3</span><span> </span><span>years the dose is 0.25ml</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>210</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Influenza</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided in the circumstances set out in subsection 7(5).</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Fluvirin</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span></span></p><p class="TableP1a"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>For children older than 6</span><span> </span><span>months but less than 9</span><span> </span><span>years, 2</span><span> </span><span>doses at least 1month apart for the first vaccination and 1 dose per calendar year after that. For persons 9</span><span> </span><span>years and above, 1 dose per calendar year.</span></p><p class="TableText0"><span>Note – For children aged between 6</span><span> </span><span>months and less than 3</span><span> </span><span>years the dose is 0.25ml</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>210A</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tabletext"><span style="font-weight:bold">Vaccine</span></p><p style="page-break-after:avoid"><span>Influenza</span></p><p class="Tabletext"><span style="font-weight:bold">Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided in the circumstances set out in subsection</span><span> </span><span>7(9A).</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Flucelvax Quad</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>For children at least 6 months of age but less than 9</span><span> </span><span>years of age, 2</span><span> </span><span>doses at least 1 month apart for the first vaccination and one dose per calendar year after that. For persons at least 9</span><span> </span><span>years of age but less than 65 years of age, one dose per calendar year.</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>210B</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="page-break-after:avoid"><span style="font-family:Arial, sans-serif; font-size:9pt; font-weight:bold">Vaccine</span></p><p style="page-break-after:avoid"><span>Influenza</span></p><p style="page-break-after:avoid"><span style="font-family:Arial, sans-serif; font-size:9pt"></span></p><p style="page-break-after:avoid"><span style="font-family:Arial, sans-serif; font-size:9pt; font-weight:bold">Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided in the circumstances set out in subsection</span><span> </span><span>7(8)</span></p><p class="Tabletext"><span style="font-weight:bold"></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="page-break-after:avoid"><span>Vaxigrip</span></p><p class="TableText0"><span></span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="page-break-after:avoid"><span>For children at least 6 months of age but less than 9 years, 2 doses at least 1 month apart for the first vaccination and 1 dose per calendar year after that.</span></p><p style="page-break-after:avoid"><span></span></p><p class="TableText0"><span>For persons 9 years and above, 1 dose per calendar year.</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>210C</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="page-break-after:avoid"><span style="font-family:Arial, sans-serif; font-size:9pt; font-weight:bold">Vaccine</span></p><p style="page-break-after:avoid"><span>Influenza</span></p><p style="page-break-after:avoid"><span style="font-family:Arial, sans-serif; font-size:9pt"></span></p><p style="page-break-after:avoid"><span style="font-family:Arial, sans-serif; font-size:9pt; font-weight:bold">Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided in the circumstances set out in subsection 7(8)</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="page-break-after:avoid"><span>Fluzone</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="page-break-after:avoid"><span>For children at least 6 months of age but less than 9 years – 2 doses at least 1 month apart for the first vaccination and 1 dose per calendar year after that.</span></p><p style="page-break-after:avoid"><span></span></p><p style="page-break-after:avoid"><span>For persons 9 years and above, 1 dose per calendar year.</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>210D</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="page-break-after:avoid"><span style="font-family:Arial, sans-serif; font-size:9pt; font-weight:bold">Vaccine</span></p><p style="page-break-after:avoid"><span>Influenza</span></p><p style="page-break-after:avoid"><span></span></p><p style="page-break-after:avoid"><span style="font-family:Arial, sans-serif; font-size:9pt; font-weight:bold">Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided in the circumstances set out in subsection</span><span> </span><span>7(9A)</span></p><p style="page-break-after:avoid"><span style="font-family:Arial, sans-serif; font-size:9pt; font-weight:bold"></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="page-break-after:avoid"><span>Flucelvax</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>For children at least 6 months of age but less than 9</span><span> </span><span>years of age, 2</span><span> </span><span>doses at least 1 month apart for the first vaccination and one dose per calendar year after that.</span></p><p class="TableText0"><span></span></p><p style="margin-bottom:3pt; page-break-after:avoid"><span>For persons at least 9</span><span> </span><span>years of age but less than 65 years of age, one dose per calendar year.</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>210E</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="page-break-after:avoid"><span style="font-family:Arial, sans-serif; font-size:9pt; font-weight:bold">Vaccine</span></p><p style="page-break-after:avoid"><span>Influenza</span></p><p style="page-break-after:avoid"><span></span></p><p style="page-break-after:avoid"><span style="font-family:Arial, sans-serif; font-size:9pt; font-weight:bold">Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to a person who is at least 65 years of age.</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="page-break-after:avoid"><span>Flublok</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; page-break-after:avoid"><span>1 dose per calendar year.</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>211</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Measles, mumps and rubella</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to a child who is:</span></p><p class="TableText0" style="margin-left:36pt; text-indent:-18pt"><span>a.</span><span style="width:10.37pt; text-indent:0pt; display:inline-block"> </span><span>about 12</span><span> </span><span>months old; or</span></p><p class="TableText0" style="margin-left:36pt; text-indent:-18pt"><span>b.</span><span style="width:9.75pt; text-indent:0pt; display:inline-block"> </span><span>about 4</span><span> </span><span>years of age if MMRV was not given at 18 months; or</span></p><p class="TableText0" style="margin-left:36pt; text-indent:-18pt"><span>c.</span><span style="width:10.37pt; text-indent:0pt; display:inline-block"> </span><span>about 18 months old when administered concurrently with a monovalent varicella vaccine.</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>M</span><span>‑</span><span>M</span><span>‑</span><span>R II</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Refrigerated lyophilised preparation for injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableP1a"><span>Each of the following live attenuated viruses:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>measles virus (Edmonston strain)</span><span> </span><span>— 1000</span><span> </span><span>TCID50;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>mumps virus (Jeryl Lynn strain)</span><span> </span><span>— 5000</span><span> </span><span>TCID50;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>rubella virus (Wistar RA 27/3</span><span> </span><span>strain)</span><span> </span><span>— 1000</span><span> </span><span>TCID50</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>1 or 2 doses</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>212</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Measles, mumps and rubella</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to a child who is;</span></p><p class="TableText0" style="margin-left:36pt; text-indent:-18pt"><span>a.</span><span style="width:10.37pt; text-indent:0pt; display:inline-block"> </span><span>about 12</span><span> </span><span>months old; or</span></p><p class="TableText0" style="margin-left:36pt; text-indent:-18pt"><span>b.</span><span style="width:9.75pt; text-indent:0pt; display:inline-block"> </span><span>about 4 years of age if MMRV was not given at 18 months; or</span></p><p class="TableText0" style="margin-left:36pt; text-indent:-18pt"><span>c.</span><span style="width:10.37pt; text-indent:0pt; display:inline-block"> </span><span>about 18 months old when administered concurrently with a monovalent varicella vaccine.</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Priorix</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Refrigerated lyophilised preparation for injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Each of the following live attenuated viruses:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>measles virus (Schwarz strain)</span><span> </span><span>— 10</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:super">3.0</span><span> </span><span>CCID</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:sub">50</span><span>;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>mumps virus (RIT 4385 derived from the Jeryl Lynn strain)</span><span> </span><span>— 10</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:super">3.7</span><span> </span><span>CCID</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:sub">50</span><span>;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>rubella virus (Wistar RA 27/3</span><span> </span><span>strain)</span><span> </span><span>— 10</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:super">3.0</span><span> </span><span>CCID</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:sub">50</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>1 or 2 doses</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>213</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Measles, mumps, rubella and varicella</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to a child who is about 18 months of age</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Priorix</span><span>‑</span><span>Tetra</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Powder for injection vial with diluent syringe (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Each of the following live attenuated viruses:</span></p><p style="margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(a)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>measles virus (Schwarz strain) – 10</span><span style="font-size:7.33pt; vertical-align:super">3.0 </span><span>CCID50</span></p><p style="margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(b)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>mumps virus (RIT 4385 strain,derived from Jeryl Lynn strain) </span><span>‑</span><span> 10</span><span style="font-size:7.33pt; vertical-align:super">4.4</span><span>CCID50</span></p><p style="margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(c)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>rubella virus (Wistar RA 27/3 strain) – 10</span><span style="font-size:7.33pt; vertical-align:super">3.0 </span><span>CCID50</span></p><p style="margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(d)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>varicella virus (Oka strain) </span><span>‑</span><span> 10</span><span style="font-size:7.33pt; vertical-align:super">3.3</span><span> PFU</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>1 dose</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>214</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Measles, mumps, rubella and varicella</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableColHead"><span style="font-family:'Times New Roman', serif; font-size:11pt; font-weight:normal">Vaccine may be provided to a child who is about 18 months of age</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>ProQuad</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Each of the following live attenuated viruses:</span></p><p style="margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(a)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>measles virus derived from Enders’ attenuated Edmonston</span><span> </span><span>strain) – 10</span><span style="font-size:7.33pt; vertical-align:super">3.0 </span><span>TCID50</span></p><p style="margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(b)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>mumps virus (Jeryl Lynn™ (B Level) strain) </span><span>‑</span><span> 10</span><span style="font-size:7.33pt; vertical-align:super">4.3</span><span>TCID50</span></p><p style="margin-left:36pt; text-indent:-18pt; line-height:normal"><span>(c)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>rubella virus (Wistar RA 27/3 strain) – 10</span><span style="font-size:7.33pt; vertical-align:super">3.0 </span><span>TCID50</span></p><p class="TableText0" style="margin-left:36pt; text-indent:-18pt"><span>(d)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>Varicella</span><span>‑</span><span>zoster virus (Oka/Merck strain) </span><span>‑</span><span> 10</span><span style="font-size:7.33pt; vertical-align:super">3.99</span><span> PFU</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>1 dose</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>215</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Poliomyelitis</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to a child who is about 2, 4 or 6 months old or 4</span><span> </span><span>years of age, if all other vaccines containing poliovirus are unsuitable</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>IPOL</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Each of the following killed whole polioviruses:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>type</span><span> </span><span>1 (Mahoney)</span><span> </span><span>— 40</span><span> </span><span>D</span><span>‑</span><span>antigen units;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>type</span><span> </span><span>2 (MEF</span><span>‑</span><span>1)</span><span> </span><span>— 8</span><span> </span><span>D</span><span>‑</span><span>antigen units;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>type</span><span> </span><span>3 (Saukett)</span><span> </span><span>— 32</span><span> </span><span>D</span><span>‑</span><span>antigen units</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>No more than 4</span><span> </span><span>doses</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>216</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Varicella</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a child who is about 18</span><span> </span><span>months old; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a child who is at least 10 years old but less than 14 years of age, if the child:</span></p><p class="TableP2i"><span style="width:25.92pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>has not had varicella; and</span></p><p class="TableP2i"><span style="width:22.86pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>has not been vaccinated against varicella.</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Varilrix</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Refrigerated lyophilised preparation for injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Live attenuated Oka strain of the varicella</span><span>‑</span><span>zoster virus</span><span> </span><span>— 10</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:super">3.3</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:super"> </span><span>PFU</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>1 dose</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>217</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Varicella</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a child who is about 18</span><span> </span><span>months old; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a child who is at least 10 years old but less than 14 years of age, if the child:</span></p><p class="TableP2i"><span style="width:25.92pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>has not had varicella; and</span></p><p class="TableP2i"><span style="width:22.86pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>has not been vaccinated against varicella.</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Varivax Refrigerated</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Refrigerated lyophilised preparation for injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Live attenuated Oka/Merck strain of the varicella</span><span>‑</span><span>zoster virus</span><span> </span><span>— at least 1350</span><span> </span><span>PFU</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>1 dose</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>217A</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tabletext"><span style="font-size:11pt; font-weight:bold">Vaccine</span></p><p class="Tabletext"><span style="font-size:11pt">Herpes zoster (shingles)</span></p><p class="Tabletext"><span style="font-size:11pt; font-weight:bold">Circumstances</span></p><p class="Tabletext"><span style="font-size:11pt">Vaccine may be provided to a person who is:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>at least 65 years of age; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>at least 50 years of age and an Aboriginal and/or Torres Strait Islander; or</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>at least 18 years of age and is considered at increased risk of herpes zoster due to:</span></p><p class="TableP2i"><span style="width:25.92pt; text-indent:0pt; display:inline-block"></span><span>(i)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>an underlying condition set out in subsection 7(15); or</span></p><p class="TableP2i"><span style="width:22.86pt; text-indent:0pt; display:inline-block"></span><span>(ii)</span><span style="width:7.1pt; text-indent:0pt; display:inline-block"> </span><span>immunomodulatory or immunosuppressive treatments in the circumstances set out in subsection 7(15).</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Shingrix</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Powder and suspension for injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p style="margin-top:3pt; margin-bottom:3pt; line-height:12pt"><span>Recombinant varicella zoster virus glycoprotein E antigen (AS01B Adjuvanted) – 50µg</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="Tablea"><span>(a) unless paragraph</span><span> </span><span>(b) applies, 2 primary doses, with the second dose given 2 to 6</span><span> </span><span>months after the first dose;</span></p><p class="Tablea"><span>(b) for persons who are immunodeficient, immunosuppressed or likely to become immunosuppressed due to known disease or therapy—2 primary doses can be given 1 to 2 months apart</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>218</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Human papillomavirus (HPV)</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>a person who is at least 12 years old but less than 14 years of age; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>A male who, between 1 February 2013 and 31 December 2015, is at least 13 years old but less than 16 years old.</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Gardasil</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Each of the following:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>HPV 6 L1 protein</span><span> </span><span>— 20</span><span> </span><span>µg;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>HPV 11 L1</span><span> </span><span>protein</span><span> </span><span>— 40</span><span> </span><span>µg;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>HPV 16 L1 protein</span><span> </span><span>— 40</span><span> </span><span>µg;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>HPV 18 L1 protein</span><span> </span><span>— 20</span><span> </span><span>µg</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>3 doses</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>218A</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Human papillomavirus (HPV) (9</span><span>‑</span><span>valent)</span></p><p class="TableColHead"><span>Circumstances</span></p><p style="text-align:justify"><span>Vaccine may be provided to:</span></p><div style="margin-left:18pt; background-color:#ffffff"><p style="margin-left:18pt; text-indent:-18pt"><span>(a)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>a person who is at least 12 years of age but less than 14 years of age; or</span></p></div><div style="margin-left:18pt; background-color:#ffffff"><p style="margin-left:18pt; text-indent:-18pt"><span>(b)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>a person who is at least 12 years of age but less than 26 years of age who has not received a single dose of HPV vaccine.</span><span></span></p></div><p class="TableColHead"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Gardasil 9</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="margin-top:0pt; margin-bottom:0pt; line-height:normal"><span>Each of the following:</span></p><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(a)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>HPV 6 L1 protein </span><span>‑</span><span> 30μg;</span></p><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(b)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>HPV 11 L1 protein </span><span>‑</span><span> 40μg;</span></p><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(c)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>HPV 16 L1 protein </span><span>‑</span><span> 60μg;</span><span></span></p><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(d)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>HPV 18 L1 protein </span><span>‑</span><span> 40μg;</span></p><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(e)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>HPV 31 L1 protein </span><span>‑</span><span> 20μg;</span><span></span></p><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(f)</span><span style="width:7.01pt; text-indent:0pt; display:inline-block"> </span><span>HPV 33 L1 protein </span><span>‑</span><span> 20μg;</span></p><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(g)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>HPV 45 L1 protein </span><span>‑</span><span> 20μg;</span><span></span></p><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(h)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>HPV 52 L1 protein </span><span>‑</span><span> 20μg;</span></p><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(i)</span><span style="width:7.62pt; text-indent:0pt; display:inline-block"> </span><span>HPV 58 L1 protein </span><span>‑</span><span> 20μg.</span></p><p class="TableText0" style="margin-top:0pt; margin-bottom:0pt; line-height:normal"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>1 dose</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>219</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Human papillomavirus (HPV)</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to:</span></p><p class="TableP1a" style="margin-left:0pt; text-indent:0.7pt"><span>a female who is at least 12 years old but less than 14 years of age.</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Cervarix</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Each of the following:</span></p><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(a)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>HPV 16 L1 protein </span><span>‑</span><span> 20μg;</span><span></span></p><p style="margin-left:17.85pt; text-indent:-17.85pt; line-height:normal"><span>(b)</span><span style="width:5.02pt; text-indent:0pt; display:inline-block"> </span><span>HPV 18 L1 protein </span><span>‑</span><span> 20μg</span><span></span></p><p class="TableP1a" style="margin-top:7.2pt; margin-bottom:7.2pt"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>2 doses</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>220</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Rotavirus</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to a child who:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>is about 2 or 4 months old.</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Rotarix</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Oral suspension (1.5mL) in oral applicator</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Human rotavirus vaccine, live attenuated, RIX 4414 strain (G1P[8])</span><span> </span><span>— not less than 10</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:super">6</span><span> CCID</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:sub">50</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>2 doses:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>first dose given at 6 to 14 weeks of age;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>second dose given at 14 to 24 weeks of age</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>221</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>Rotavirus</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to a child who:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>is about 2, 4 or 6 months old.</span></p><p style="text-align:right"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>RotaTeq</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Oral solution (2.0mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Live pentavalent reassortant vaccine containing each of the following:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>G1</span><span> </span><span>— 2.2 x 10</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:super">6</span><span style="font-size:7.33pt; vertical-align:super"> </span><span>IU;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>G2</span><span> </span><span>— 2.8 x 10</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:super">6</span><span style="font-size:7.33pt; vertical-align:super"> </span><span>IU;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>G3</span><span> </span><span>— 2.2 x 10</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:super">6</span><span style="font-size:7.33pt; vertical-align:super"> </span><span>IU;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(d)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>G4</span><span> </span><span>— 2.0 x 10</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:super">6</span><span style="font-size:7.33pt; vertical-align:super"> </span><span>IU;</span></p><p class="TableText0"><span></span><span>(e)</span><span> </span><span>P1</span><span> </span><span>(8)</span><span> </span><span>— 2.3 x 10</span><span style="font-family:'Times New (W1)', serif; font-size:7.33pt; vertical-align:super">6</span><span style="font-size:7.33pt; vertical-align:super"> </span><span>IU</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>3 doses:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>first dose given at 6 to 14 weeks old;</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>second dose given at 14 to 24 weeks old;</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(c)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>third dose given before 32 weeks old</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>222</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>respiratory syncytial virus (RSV) stabilised prefusion F subunit</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to a person who is pregnant</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Abrysvo</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Each 0.5mL dose contains 120 µg of stabilised prefusion F proteins (60 µg</span><span> </span><span>RSV</span><span>‑</span><span>A and 60 µg</span><span> </span><span>RSV</span><span>‑</span><span>B antigens)</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>1 dose:</span></p><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(a)</span><span style="width:5.79pt; text-indent:0pt; display:inline-block"> </span><span>at 28 to 36 weeks gestation; or</span></p><p style="margin-left:18pt; text-indent:-18pt; line-height:normal"><span>(b)</span><span style="width:5.17pt; text-indent:0pt; display:inline-block"> </span><span>after 36 weeks gestation, if vaccination is two weeks prior to birth.</span></p></td></tr><tr><td style="width:5.44%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0" style="text-align:right"><span>223</span></p></td><td style="width:31.08%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableColHead"><span>Vaccine</span></p><p class="TableText0"><span>respiratory syncytial virus (RSV) stabilised prefusion F protein (AS01</span><span style="font-size:7.33pt; vertical-align:sub">E</span><span> adjuvanted)</span></p><p class="TableColHead"><span>Circumstances</span></p><p class="TableText0"><span>Vaccine may be provided to person who is:</span></p><p class="TableP1a"><span style="width:8.19pt; text-indent:0pt; display:inline-block"></span><span>(a)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>at least 75 years of age; or</span></p><p class="TableP1a"><span style="width:7.57pt; text-indent:0pt; display:inline-block"></span><span>(b)</span><span style="width:6.25pt; text-indent:0pt; display:inline-block"> </span><span>an Aboriginal and/or Torres Strait Islander and aged between 60 and 74 years.</span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Arexvy</span></p></td><td style="width:13.24%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Injection (0.5mL)</span></p></td><td style="width:23.42%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>Each 0.5mL dose contains 120 μg of recombinant respiratory syncytial virus pre-fusion F protein</span><span> </span><span>(RSVPreF3) antigen adjuvanted with AS01</span><span style="font-size:7.33pt; vertical-align:sub">E</span><span>.</span></p><p class="TableText0"><span></span></p></td><td colspan="2" style="padding-right:5.4pt; padding-left:5.4pt; vertical-align:top"><p class="TableText0"><span>1 dose</span></p></td></tr><tr style="height:0pt"><td style="width:36.55pt"></td><td style="width:209.2pt"></td><td style="width:0.4pt"></td><td style="width:92.05pt"></td><td style="width:89.1pt"></td><td style="width:157.65pt"></td><td style="width:87.8pt"></td><td style="width:0.3pt"></td></tr></tbody></table>